Article | Patients1 | Age, sex2 | Emergent indication | BMI3 | ASA | Type of hernia | Use of mesh | Additional surgery | Hospital stay4 | Main complications | Recurrences |
---|---|---|---|---|---|---|---|---|---|---|---|
Dubina [24] | 266/3334 | 68 ± 14, 71% male | Obstruction or gangrene | n.a. | I–II (40%), III–IV (60%)a | n.a. | n.a. | n.a. | 5 ± 7 | Overall morbidity (11%), pneumonia (4%)a | n.a. |
Shea [25] | 30/229 | 74 ± 13, 80% male | Volvulus (47%), bleeding (17%), obstruction (20%), heart/respiratory failure (13%) | 29 ± 6 | II (23%), III (67%), IV (10%) | III (67%), IV (33%) | Acellular porcine liver derived (100%) | Nissen (100%), gastrostomy (13%), gastric resections (23%) | 7 ± 6 | Overall morbidity (47%) | 17% |
Zanotti [26] | 1/4 | 73, female | Volvulus | n.a. | n.a. | III | Synthetic partially absorbable | Nissen | 7 | Pneumonia | No |
Arevalo [27] | 4/13 | 85 ± 9, sex n.a. | Bleeding (25%), obstruction (100%) | n.a. | III (50%), IV (50%) | n.a. | None | Gastropexy and gastrostomy (100%) | 7 (2–14) | Reoperation for early recurrence (25%) | No |
Augustin [28] | 56/3498 | 71, 36% male | SIRS/sepsis/septic shock (30%)b | 26 (25-28)b | III–IV (22%)b | n.a. | n.a. | n.a. | 9 (7-10)b | Infections (7%), sepsis/shock (8%), reoperation (9%), heart/lung complications (28%), others (7%)b | n.a. |
Light [29] | 9/36 | 73c | Gastric volvulus (100%)c | n.a. | III–IV (73%)c | n.a. | None (no hiatal repair in 11%)c | Dor (22%), Nissen (8%), gastropexy (31%), gastric resections (11%)c | 4 | Pneumonia (25%), others (11%)c | 2% |
Klinginsmith [30] | 1358/7950 | 65 ± 14, 48% maled | n.a. | n.a. | n.a. | n.a. | n.a. | Fundoplication (38%), gastrostomy (12%) | n.a. | Overall morbidity (8%) | n.a. |
Köhler [31] | 3/24 | 64 ± 14, 42% malee | Obstruction (100%) | n.a. | n.a. | n.a. | Synthetic (75%)e | Toupet (25%), Nissen (75%), gastropexy | n.a. | Pneumonia (33%), splenic bleeding (33%) | 1%e |
Jassim [32] | 2896/41723 | 66, 35% malef | n.a. | Obesity (7%)f | n.a. | n.a. | n.a. | n.a. | n.a. | Overall morbidity (33%)f | n.a. |
Mungo [33] | 116/8186 | 63 ± 14, 28% maleg | n.a. | < 25 (18%), 25–29.9 (27%), ≥ 30 (45%)g | II (56%), III (43%), IV (2%)g | n.a. | n.a. | n.a. | 3 ± 5g | Overall morbidity (8%), reoperation (3%), pneumonia (2%), sepsis/shock (1%), heart/lung complications (4%)g | n.a. |
Gebhart [34] | 3/92 | 57 ± 14, 40% male h | Incarceration | n.a. | n.a. | IV (2%)h | Biosynthetic (some cases) | Nissen (73%)h | 2 ± 3h | Overall morbidity (6%)h | 19%h |
Parker [35] | 25/266 | 75 (51–91), 12% male | Obstruction, haemorrhage, perforation, sepsis from gastric ischemia | 30 | n.a. | II (4%), III (92%), IV (4%) | Synthetic or acellular human dermal matrix (85%) | Nissen or Dor (76%), Collis (24%) | 4 (1–13) | Overall morbidity (52%), heart/lung complications (24%), pneumonia (4%), infections (4%), leak (12%) | 4% |
Ballian [36] | 24/980 | < 50 (15%), 50–59 (12%), 60–69 (10%), 70–79 (17%), ≥ 80 (47%), 25% malei | n.a. | Underweight (44%), ideal (32%), overweight (17%), obese (15%), severely obese (15%)i | n.a. | n.a. | Unpecified (12%)j | Dor or Toupet (21%), Nissen (70%), Collis (47%)j | n.a. | Overall morbidity (23%), pneumonia (7%), heart/lung complication (18%), sepsis/shock (2%), leak (2%)j | 1%j |
Shaikh [37] | 11/64 | 68 ± 2, 25% male | n.a. | n.a. | n.a. | n.a. | Porcine small intestine submucosa matrix used in 3 cases unspecified if emergent/elective, laparoscopic/open | Fundoplication (65%), gastropexy (13%), gastropexy only (25%)k | 6 ± 2††† | Overall morbidity (23%)k | 25%k |
Louie [38] | 9/58 | 78 (70–91), 41% malel | Incarceration (100%) | n.a. | n.a. | II (5%), III (78%), IV (17%)l | Biologic (38%)‡ | Nissen (31%), Hill (33%), combined Nissen and Hill (34%), gastrostomy (2%)l | n.a. | Lung complications (11%) | 11% |
Bawahab [39] | 17/20 | 71 (49–91), 15% malem | Obstruction, bleeding, respiratory failure | n.a. | n.a. | n.a. | Porcine small intestine submucosa matrix (6%) | Nissen or Dor (100%) | 7 (2–15) | 0% | n.a. |
Parameswaran [40] | 5/49 | 68 (38–90), 41% malen | n.a. | n.a. | III–IV (41%)n | II (10%), III (73%), IV (16%)n | PFTE or composite (22%), porcine small intestine submucosa matrix (12%)n | Nissen (100%), gastropexy in some casesn | n.a. | Overall morbidity (24%)n | 8%‡‡‡ |
Hortsmann [41] | 16 | 64 (36–80), 50% male | Obstruction | 29 (19–31) | II (31%), III (69%) | n.a. | Polypropylene (100%) | Toupet (100%), gasropexy (100%) | 9 (7–23) | Lung complications (31–38%) | 0% |